Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Manual for Tracking down the Mysterious Cascades in China - 2Ariana Grande and Jonathan Bailey will reunite for 'Sunday in the Park With George'
- 3Revealing the Incomparable Realms: An Excursion through Power and Inheritance
- 4Artemis 2 astronauts reveal adorable zero-g indicator 'Rise' | Space photo of the day for March 31, 2026
- 5Iranian naval commander Alireza Tangsiri killed in attack, says Israel
- Instructions to Construct an Organization While Chasing after a Web-based Degree
- Instructions to Expand Your Smash 1500's Presentation: Tips and Deceives
- A Republican elected governor in California? It's not as far-fetched as it sounds.
- Excelling at Discussion: Genuine Examples of overcoming adversity
- The Solution to Innovative Peculiarity: Analyzing the Fate of Mankind
- Artemis 2 breaks humanity's all-time distance record during historic loop around the moon (video)
- Instructions to Upgrade the Proficiency of Your Sunlight powered chargers
- 21 Things You Ought to Never Tell Your Childless Companion
- Excursion to Different Universes: the Top Sci-fi Motion pictures Ever
